THE DEAL, AT A GLANCE
From the announcementTotient
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedTotient raised $21M SeedFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersTotient is applying AI protein language models to antibody engineering, using Seed funding to build a computational antibody discovery platform for pharma partnerships.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Totient · Financing Record
Explore source-linked visual explanations for Totient. Unsupported claims are withheld while source review continues.
Record 1216 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →